Sequencing Study Suggests Mutation Selection Behind Glitches in Therapy-related AML | GenomeWeb

NEW YORK (GenomeWeb) – The risk of developing tricky-to-treat leukemia in the years following treatment for other types of cancer appears to reflect selection for cells containing treatment resistance-related mutations that are already circulating in the body, according to a new study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
08
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.